1 **Diagnosis of acute myocardial infarction in the presence of left bundle-branch block**

2
3 Thomas Nestelberger, MD^{1,2*}; Louise Cullen, MD, PhD^{3*}; Bertil Lindahl, MD⁴; Tobias
4 Reichlin, MD^{1,2}; Jaimi Greenslade, PhD³; Evangelos Giannitsis, MD⁵; Michael Christ, MD⁶;
5 Beata Morawiec, MD⁷; Òscar Miró, MD⁸; Francisco Javier Martín-Sánchez, MD⁹; Desiree
6 Wussler, MD^{1,2}; Luca Koechlin, MD^{1,2}; Raphael Twerenbold, MD^{1,2,10}; William A.
7 Parsonage, MD³; Jasper Boeddinghaus, MD^{1,2}; Maria Rubini Giménez, MD^{1,2}; Christian
8 Puelacher, MD, PhD^{1,2}; Karin Wildi, MD^{1,2}; Tobias Buerge, MD¹; Patrick Badertscher,
9 MD^{1,2}; Jeanne du Fay de Lavallaz, MD^{1,2}; Ivo Strebel, PhD^{1,2}; Lukas Croton, MS¹; Garnet
10 Bendig, PhD¹¹; Stefan Osswald, MD¹; John Pickering, PhD¹²; Martin Than, MD¹²; Christian
11 Mueller, MD^{1,2} for the APACE, ADAPT, and TRAPID-AMI Investigators.

12 ¹Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University
13 Hospital Basel, University of Basel, Switzerland; ²GREAT network; ³Royal Brisbane &
14 Women's Hospital, Herston, Australia; ⁴Department of Medical Sciences, Uppsala University
15 and Uppsala Clinical Research Centre, Uppsala University, Sweden; ⁵Medizinische Klinik III,
16 University Heidelberg, Germany; ⁶Department of Emergency Care, Lucerne General
17 Hospital, Lucerne, Switzerland; ⁷2nd Cardiology department, Zabrze, University Silesia,
18 Katowice, Poland; ⁸Emergency department, Hospital Clinic, Barcelona, Catalonia, Spain;
19 ⁹Emergency department, Hospital Clinico San Carlos, Madrid, Spain; ¹⁰Department of
20 General and Interventional Cardiology, Hamburg University Heart Center, Hamburg,
21 Germany; ¹¹Roche Diagnostics, Penzberg, Germany; ¹²Christchurch Hospital, Christchurch,
22 New Zealand

23 *both authors have contributed equally and should be considered first author

24 Word count: 2910

26 **Short title:** Acute Myocardial Infarction in Left Bundle Branch Block

27 **Correspondence to:** Prof. Dr. Christian Müller, Department of Cardiology, University
28 Hospital Basel; Petersgraben 4, CH-4031 Basel, Switzerland. Phone Number: +41 61 328 65
29 49; E-mail: christian.mueller@usb.ch

33 **Key questions**

34 **What is already known about this subject?**

35 Patients with suspected acute myocardial infarction (AMI) in the setting of left bundle branch
36 block (LBBB) present an important diagnostic and therapeutic challenge to the clinician.

37 **What does this study add?**

38 Specific ECG criteria in LBBB patients including concordant ST-segment elevation (criteria
39 1) or depression (criteria 2) or pronounced discordant ST-segment elevation (criteria 3) in
40 specific ECG leads and an alternative ECG criteria including ST-segment depression or
41 elevation discordant with the QRS complex with a magnitude of at least 25% of the QRS
42 complex (alternative criteria 3) together with suggested (h)s-cTn thresholds (e.g. hs-cTnT
43 ≥ 42 ng/l at presentation) allow an accurate and immediate triage to coronary angiography in
44 patients with LBBB and symptoms suggestive of AMI.

45 **How might this impact on clinical practice?**

46 An integrated triage-algorithm including specific ECG criteria with high specificity, as well
47 as hs-cTnT/I concentrations at presentation and their 0/1h- or 0/2h-changes provides high
48 diagnostic accuracy and efficacy helping in the selection of patients for immediate and/or
49 early coronary angiography.

ABSTRACT

Objective: Patients with suspected acute myocardial infarction (AMI) in the setting of left bundle branch block (LBBB) present an important diagnostic and therapeutic challenge to the clinician.

Methods: We prospectively evaluated incidence of AMI, and diagnostic performance of specific electrocardiographic (ECG) and high-sensitivity cardiac troponin (hs-cTn) criteria in patients presenting with chest discomfort to 26 emergency departments in three international, prospective, diagnostic studies. The final diagnosis of AMI was centrally adjudicated by two independent cardiologists according to the universal definition of myocardial infarction.

Results: Among 8830 patients, LBBB was present in 247 patients (2.8%). AMI was the final diagnosis in 30% of patients with LBBB, with similar incidence in those with known LBBB versus those with presumably new LBBB (29% vs 35%, $p=0.42$). ECG criteria had low sensitivity (1-12%), but high specificity (95-100%) for AMI. The diagnostic accuracy as quantified by the receiver-operating-characteristics curve of hs-cTnT and hs-cTnI concentrations at presentation (AUC 0.91; 95%CI 0.85–0.96 and 0.89; 95% CI 0.83-0.95) as well as that of their 0/1h- and 0/2h-changes was very high. A diagnostic algorithm combining ECG criteria with hs-cTnT/I concentrations and their absolute changes at 1h or 2h derived in cohort 1 (45 of 45 (100%) of patients with AMI correctly identified), showed high efficacy and accuracy when externally validated in cohort 2&3 (28 of 29 patients, 97%).

Conclusion: Most patients presenting with suspected AMI and LBBB will be found to have diagnoses other than AMI. Combining ECG criteria with hs-cTnT/I testing at 0/1h or 0/2h allows early and accurate diagnosis of AMI in LBBB.

Keywords

- 73 left bundle branch block, electrocardiography, high sensitivity cardiac troponin; acute
- 74 myocardial infarction
- 75 **Registration Numbers**
- 76 APACE: NCT00470587; ADAPT: ACTRN12611001069943; TRAPID-AMI: RD001107

INTRODUCTION

Patients with symptoms suggestive of acute myocardial infarction (AMI) account for approximately 10% of all emergency department (ED) consultations. Rapid identification of AMI as life-threatening disorder is important for the early initiation of highly effective, evidence-based therapy.⁽¹⁾⁽²⁾⁽³⁾ Patients presenting with suspected AMI and left bundle branch block (LBBB) to the ED represent a unique diagnostic and therapeutic challenge, as altered ventricular depolarization masks changes in ventricular repolarization associated with myocardial ischemia.⁽²⁾

In patients presenting with ST-segment elevation MI (STEMI), who usually can be rapidly identified with the 12-lead ECG, enormous improvements in outcomes have been achieved.⁽¹⁾⁽²⁾ These patients derive major benefit from immediate coronary reperfusion.⁽¹⁾⁽²⁾ It is currently unknown, how AMI can best be diagnosed early in patients presenting with suspected AMI and LBBB.⁽¹⁾⁽²⁾ This major uncertainty is highlighted by divergent recommendations given by the respective clinical practice guidelines in the United States and Europe.⁽¹⁾⁽²⁾ Current European Society of Cardiology (ESC) guidelines stated that patients with LBBB should be managed in a way similar to STEMI patients.⁽²⁾ In contrast, current American Heart Association (AHA) and American College of Cardiology (ACC) guidelines interpret LBBB not to be diagnostic for AMI.⁽¹⁾ Too liberal interpretation of LBBB could lead to thousands of unnecessary cardiac catheterization laboratory activations and thousands of patients inappropriately given thrombolytic therapy each year, increased risk of complications related to inappropriate invasive procedures, prolonged hospitalization, higher treatment costs and decreased quality of life for patients.⁽⁴⁾⁽⁵⁾⁽⁶⁾ In contrast, too restrictive interpretation of LBBB could withhold life-saving immediate reperfusion therapy from patients with large AMIs and could ultimately increase mortality.⁽⁴⁾⁽⁷⁾

102 In order to address this important gap in knowledge, we aimed to first, evaluate the
103 incidence of AMI among patients with suspected AMI and LBBB in the recorded at ED
104 presentation, and second, to develop a comprehensive strategy for the early diagnosis of AMI
105 in patients with LBBB.(4)(8)(9)

METHODS

Study design and oversight

We enrolled adult patients presenting with suspected AMI to the ED in three large prospective multicenter diagnostic studies carried out according to the principles of the Declaration of Helsinki and approved by the local ethics committees. These are Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) (10)(11)(12) Accelerated Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary Troponins as the only biomarker (ADAPT),(13) and High-sensitivity cardiac Troponin T assay for RAPID rule-out of AMI (TRAPID-AMI)(14). Written informed consent was obtained from all patients (**Online Table 1**).

The authors designed the study, gathered, analyzed and reported the data according to the STARD guidelines for studies of diagnostic accuracy(15) (**Online Table 2**), vouch for the data and analysis, wrote the paper, and made the decision to submit it for publication. The sponsors had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication.

Methodology of all three cohorts

In all three cohorts, we included unselected patients presenting to the ED with acute chest discomfort. All patients underwent a clinical assessment that included standardized and detailed medical history including assessment of chest pain characteristics, vital signs, physical examination, 12-lead ECG, continuous ECG rhythm monitoring, pulse oximetry, standard blood test, and chest radiography and echocardiography if indicated. Treatment of patients was left to discretion of the attending physician.

Detailed methodical descriptions of all 3 cohorts including study -design, -dates and -centers, eligibility criteria and study population, routine clinical assessment, adjudication of final diagnoses, follow-up and clinical endpoints are shown in the Appendix. An overview of study specific characteristics including investigational high-sensitivity cardiac troponin (hs-cTn) measurements, adjudication of final diagnoses and specific ECG criteria for all 3 cohorts are shown in **Online Table 1** and described in detail within the Appendix.

Adjudication of specific ECG criteria

ECG adjudication was performed centrally for all 3 cohorts by at least 2 independent cardiologists blinded to all clinical information and using predefined criteria.(16)(17) LBBB criteria were a QRS duration of more than 120ms, dominant S wave in V1, broad monophasic R wave in lateral leads (I, aVL, V5-V6), an absence of Q waves in lateral leads (I, V5-V6; small Q waves were still allowed in aVL) and prolonged R wave peak time > 60ms in left precordial leads (V5-6).

ECG criteria 1 to 3(16) included ST-segment elevation of 0.1 mV or more concordant with the QRS complex in any lead (ECG criteria 1, 5 points), concordant ST-segment depression of 0.1 mV or more in lead V1, V2, or V3 (ECG criteria 2, 3 points) and ST-segment elevation of 0.5 mV or more discordant with the QRS complex in any lead (ECG criteria 3, 2 points; **Online Figure 1A**). A score of ≥ 3 was suggested for the diagnosis of acute coronary occlusion within the original publication (ECG score ≥ 3). (16) The alternative ECG criteria 3 (17) were proposed to be superior to the original ECG criteria 3 and is defined as a negative ST/S ratio < -0.25 and at least 0.1 mV of ST segment elevation in any lead, (alternative ECG criteria 3, 2 points, **Online Figure 1B**)(18). Again, a score of ≥ 3 was suggested for the diagnosis of acute coronary occlusion (alternative ECG score ≥ 3). In case of

presence of LBBB on a previous ECG, LBBB was classified as known. Otherwise it was classified as presumably new. A differentiation between new and new presumably LBBB was not possible, because exact onset of LBBB could not be determined in most patients. Differentiation between known and presumably new LBBB was possible in cohort #1 by retrieving previous ECG recordings from the electronic ECG storage systems of the participating institutions as well as the general practitioner in the vast majority of patients, but not in cohort #2 and #3.

Case studies for three patients presenting with suspected AMI and LBBB are described in **Online Figure 2**, including their clinical presentation, medical history, ECG at presentation, hs-cTnT concentrations, coronary angiography results, follow-up information and adjudication diagnoses.

Statistical analysis

The data are expressed as medians $\pm$ interquartile range (IQR) for continuous variables, and for categorical variables as numbers and percentages. All variables between known LBBB and presumably new LBBB or LBBB with or without AMI were compared by Student's t Test or Mann-Whitney-U test for continuous variables or Pearson chi-square or Fisher's Exact test for categorical variables. Receiver-operating characteristics (ROC) curves were constructed to assess the sensitivity and specificity for concentrations of hs-cTnT/I at presentation and their 1h or 2h absolute changes. A positive predictive value (PPV) of 80% was considered necessary to proceed with early coronary angiography(19) for the derivation of cut-off concentrations. In cohort #1 (derivation cohort) we performed a univariate regression analysis using the selection operator LASSO to find predictors for the model. Variables who entered this model have been previously selected based on their availability in

all 3 cohorts, shown differences within the baseline characteristics tables and based on their clinical importance. Additionally, the numbers of variables were restricted to the number of events (AMI in patients with LBBB). In cohort #2 and cohort #3 (validation cohorts) we used the same variables as in cohort #1, if they have shown a statistically significant difference. All hypothesis testing was two-tailed, and P values of less than 0.05 were considered to indicate statistical significance. All statistical analyses were performed with the use of IBM SPSS Statistics for Windows, version 24.0 (SPSS Version 24, Inc Chicago, IL).

198

199

200

201 **Results**

202 **Study population**

203 Overall, 8830 patients were available for analysis (**Online Figure 3**). LBBB was present in
204 247 patients (2.8%; **Figure 1A**). AMI was the final diagnosis in 30% (75 of 247 patients,
205 **Figure 1B**) of patients with LBBB, with similar incidence in those with known LBBB versus
206 those with presumably new LBBB (29% vs 35%, $p=0.42$). Patients with known LBBB had
207 similar baseline characteristics as those with presumably new LBBB. (**Online Table 3**)
208 Patients with LBBB were older, had more cardiovascular risk factors and more often
209 preexisting cardiac disease, including coronary artery disease (CAD) in 54% as compared to
210 33% in the overall population (**Table 1, Online Tables 4-8**).

211

212 **Echocardiography**

213 Echocardiographic findings were similar in LBBB patients with AMI as compared to LBBB
214 patients without AMI (**Online Table 9**). Most patients with LBBB had moderately reduced
215 left ventricular ejection fraction (LVEF, median 40%), a dilated left atrium (70%), left
216 ventricular hypertrophy (56%) and wall motion abnormalities (79%).

217

218 **Coronary intervention**

In patients with AMI and LBBB coronary intervention were performed in the left anterior descending coronary artery in 16%, in the left circumflex artery in 13%, in a venous bypass graft in 8.9%, and in the right coronary artery in 4.4% (**Table 1**).

ECG criteria

Seventeen patients (12%) fulfilled at least one of the specific ECG criteria for AMI detection. Each criteria or their combination in a score had a sensitivity ranging from 1% to 12% and a specificity ranging from 95% to 100% (**Table 2, Online Figure 4A**). We found no differences for specific ECG criteria pertaining to the culprit lesion. Thirteen percent of patients with specific ECG criteria were found to have the culprit lesion in the left main vessel, RIVA, RCX or ACD, respectively.

Hs-cTnT/I

Blood concentrations of hs-cTnT and (h)s-cTnI at presentation and their early absolute changes were significantly higher in LBBB patients with AMI as compared to those with other final diagnoses (**Online Figure 5**). Diagnostic accuracy as quantified by the area under the ROC curve (AUC) was very high (at presentation AUC for hs-cTnT 0.91; 95%CI 0.85–0.96; and AUC for hs-cTnI 0.89, 95% CI 0.83-0.95; **Table 3**). Hs-cTnT levels ≥ 42 ng/L (hs-cTnI ≥ 45 ng/L, s-cTnI ≥ 52 ng/L) provided a PPV of 80% (95% CI, 64-90%) for AMI and together with known CAD (odds ratio 4.6, 95%CI 2.0–10.4) predicted AMI in multivariate analysis in LBBB patients (odds ratio 31.4, 95%CI 10–98.7; **Table 3; Online Table 10, Online Figure 4B**).

Suggested diagnostic work-up

In cohort #1 at least one specific ECG criteria were positive in 17/140 (12%) of patients with LBBB and suspected AMI, of whom 8 (47%) patients had an AMI. 38/140 patients had hs-cTnT concentration at presentation $\geq 42\text{ng/L}$, of whom 29 (76%) patients had an AMI. 11/140 (8%) had an hs-cTnT 0/1h absolute change concentration $\geq 3\text{ng/L}$, of whom 8 (73%) had an AMI (**Figure 1**). In both validation cohorts using this step-by-step approach resulted in similar findings and high accuracy to identify patients for the suggested work-up. (**Figure 2 and 3**).

The performance of the individual ECG criteria, of hs-cTnT and hs-cTnI in general, and their respective cut-off concentrations optimized for use in patients with LBBB in particular, were similar among the three cohorts.

DISCUSSION

This analysis is based on three large prospective multicenter diagnostic studies with central adjudication of AMI by independent cardiologists applying the universal definition of AMI(3). It was performed to contribute to advancing the clinical care of patients presenting with symptoms suggestive of AMI and LBBB to the ED. We report five major findings.

First, 2.8% of patients presenting with suspected AMI to the ED had LBBB. These patients were older and more often had preexisting cardiovascular disorders including CAD. Second, the majority of patients presenting with suspected AMI and LBBB were finally found to have non-cardiac disorders and cardiac disorders other than AMI. The incidence of AMI was 30% in LBBB patients, and similar in patients with known LBBB versus new/presumably new LBBB. Third, specific ECG criteria had low sensitivity, but high specificity for AMI. Integrating the alternative ECG criteria 3 to the specific ECG score resulted in a sensitivity of 12% and specificity of 97%. Fourth, diagnostic accuracy of hs-cTnT and hs-cTnI concentrations at ED presentation and their early changes within 1h or 2h was very high. In addition, together with a history of known CAD hs-cTnT/I concentrations at presentation predicted the presence of AMI in multivariate analysis. Hs-cTnT concentrations at presentation with a predefined PPV of at least 80% for AMI were 42ng/L or higher (hs-cTnI ≥ 45 ng/L, s-cTnI ≥ 52 ng/L). Interestingly, these (h)s-cTnT/I cut-off levels providing a PPV for AMI of 80% in patients with LBBB were similar to those recommended in current ESC guidelines for the rule-in of AMI in general. (20) Fifth, a novel triage algorithm integrating specific ECG criteria as the first step, hs-cTnT/I at presentation as the second, and the 0/1h absolute change in hs-cTnT/I as the third step, provided high accuracy and efficacy for the early detection of AMI and thereby for the selection of patients for immediate and early coronary angiography in both the derivation and external validation cohort.

These findings from 8830 patients presenting with suspected AMI to the ED extend and corroborate previous work on patients with LBBB.(16)(17)(21)(22)(23)(24)(25)(26) Results derived from selected patients enrolled in clinical trials of new pharmacologic therapies had indicated that patients with likely AMI who have new or presumably new LBBB should undergo rapid reperfusion therapy.(2) This strategy has recently been challenged by retrospective single-center studies from unselected ED cohorts or STEMI-networks suggesting that most patients with symptoms suggestive of AMI with new or presumably new LBBB do not have AMI.(23)(24)(27)(28)(29)(30) However, these studies had important methodological limitations including retrospective design, use of administrative coding for AMI, use of cardiac biomarkers with poor sensitivity such as CK-MB or previous generation cTn, and lack of adherence to the universal definition of AMI.(1)(2)

Our study overcomes these limitations and provides detailed guidance on how currently available diagnostic tools can best be used in patients with LBBB to balance the benefits and risks associated with early coronary angiography.(1)(2) Only one third of patients presenting with symptoms suggestive of AMI and LBBB to the ED will be found to have AMI as final diagnosis, irrespective of known or presumably new LBBB. Due to their high specificity, specific ECG criteria should be used to immediately triage patients towards rule-in of AMI and immediate coronary angiography such as in STEMI patients (around 6-12% of patients with LBBB). Patients not meeting these ECG criteria do have only a slightly higher overall incidence of AMI as compared to patients without LBBB and should undergo standard testing for hs-cTn.(1)(2)(8)(13)(14) Already the measurement at presentation provides very high diagnostic accuracy and allows to rapidly rule-in additional patients for early coronary angiography, if hs-cTn blood concentrations are substantially elevated ($\approx 15\%$ of patients with LBBB).(8)(13)(14)(20) In all remaining patients, the second hs-cTn blood concentration determined 1h to 2h after presentation will allow to identify additional AMI

patients in case of a relevant absolute change and triage them for early coronary angiography. In patients not meeting any of the three rule-in criteria, the likelihood of having AMI is very low. Still, as with all other early triage algorithm, detailed clinical assessment including chest pain characteristics and possibly additional hs-cTnT/I measurements at 3h helps selecting the most appropriate cardiac imaging modality to follow: echocardiography, non-invasive stress imaging, coronary computed tomography angiography, coronary angiography, or none in patients in whom the diagnostic work-up already has established a definite alternative cause of acute chest discomfort at that time such as pneumonia or pulmonary embolism (**Figures 1-3 and Online Figure 6A-B**).⁽¹⁹⁾

Among LBBB patients with AMI, culprit lesions most often were in the RIVA and RCX. This distribution differs from all-comers with AMI. ⁽¹⁶⁾⁽¹⁷⁾⁽²¹⁾⁽²²⁾⁽²³⁾⁽²⁴⁾⁽²⁵⁾⁽²⁶⁾

Potential limitations of the present study merit consideration. First, while a relevant percentage of patients had LBBB recorded on a previous ECG and were classified as known LBBB, as in all previous studies, the exact onset of LBBB was unknown in many patients and LBBB had to be classified as new or presumably new in APACE. This inherent limitation can only be overcome in patients with implantable devices such as pacemakers and loop recorders. In cohort #2 and #3, limited data on previous ECGs were available, therefore differentiation between known LBBB and presumably new LBBB was not possible for all patients. Second, although all three studies tried to be broad in the exact definition of its inclusion criteria in order to reflect the clinical challenge, we wish to acknowledge that it is unclear whether the findings of this study can also be extrapolated to AMI patients presenting with uncommon symptoms such as e.g. exclusively with weakness.⁽³¹⁾ Third, our findings were derived from patients presenting with symptoms suggestive of AMI to the ED. While our study designs ensure the generalizability to this setting, our findings may not apply to settings with a much lower pretest probability for AMI such as patients presenting to a

general practitioner, and settings with a much higher pretest probability such as patients in shock or after cardiac arrest transferred directly to a catheter laboratory. Additional studies are necessary in these settings. Fourth, this study required written informed consent. Accordingly, our findings may not apply to critically ill patients unable to provide informed consent, such as patients after cardiac arrest or patients in cardiogenic shock. These patients were eligible only in cohort #2, where a retrospective consent or a consent given by family members was possible. Unfortunately, this limitation also applies to diagnostic tests in general. Fifth, we cannot comment on LBBB in patients with terminal kidney failure, as these patients were excluded in cohort #1 and #3.

In conclusion, most patients presenting with symptoms suggestive of AMI and LBBB to the ED will be found to have diagnoses other than AMI and should not be considered a STEMI equivalent. An integrated triage-algorithm including specific ECG criteria with high specificity, as well as hs-cTnT/I concentrations at presentation and their 0/1h- or 0/2h-changes provides high diagnostic accuracy and efficacy helping in the selection of patients for immediate and/or early coronary angiography.

Additional APACE, ADAPT, and TRAPID-AMI Investigators and contributors to this manuscript were:

Petra Hillinger, MD^{1,2}; Karin Grimm, MD^{1,2}; Ursina Honegger, MSc¹; Nicolas Schaerli, MD^{1,2}; Nikola Kozhuharov, MD^{1,2}; Samyut Shrestha, MD^{1,2}; Claudia Stelzig, MSc¹; Michael Freese, SN¹; Zaid Sabti, MD^{1,2}; Joan Walter, MD^{1,2}; Lorraine Sazgary, MD^{1,2}; Caroline Kulangara, PhD¹; Kathrin Meissner, RN¹; Deborah Mueller, MD^{1,2}; Beatriz Lopez, MD^{2,3}; Emilio Salgado, MD^{2,3}; Esther Rodríguez Adrada, MD⁴; Damian Kawecki MD⁵; Jiri Parenica, MD⁶; Eva Ganovska, MD⁶; Katharina Rentsch, PhD⁷; Andreas Buser, MD⁸; Jens Lohrmann,

MD¹; Roland Bingisser, MD⁹; Samyut Shrestha, MD¹; Fabio Stallone, MD¹; Roger
 Abaecherli, PhD^{1,2}; James McCord, MD,¹⁰ Richard Nowak, MD¹¹; Richard Body, PhD^{11,12};
 Christopher R. deFilippi, MD¹³; Robert H. Christenson, PhD¹⁴; Mauro Panteghini, MD¹⁵;
 Mario Plebani, MD¹⁶; Franck Verschuren, MD¹⁷; John French, PhD¹⁸; Silvia Weiser, PhD¹⁹;
 Carina Dinkel, PhD¹⁹; Dagmar I. Keller, MD²⁰; Nicolas Geigy, MD²¹.

¹Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University
 Hospital Basel, Switzerland; ²GREAT network; ³Emergency department, Hospital Clinic,
 Barcelona, Catalonia, Spain; ⁴Emergency department, Hospital Clinico San Carlos, Madrid,
 Spain; ⁵2nd Cardiology department, Zabrze, University Silesia, Katowice, Poland; ⁶University
 Hospital Brno, Czech Republic; ⁷Laboratory Medicine, University Hospital Basel,
 Switzerland; ⁸Blood Bank and Department of Hematology, University Hospital Base,
 Switzerland; ⁹Emergency Department, University Hospital Basel, Switzerland; ¹⁰Henry Ford
 Heart & Vascular Institute, Henry Ford Health System, Detroit, Michigan, USA; ¹¹Emergency
 Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester
 Academic Health Sciences Centre, Manchester, United Kingdom; ¹²Cardiovascular Sciences
 Research Group, University of Manchester, Oxford Road, Manchester, United Kingdom;
¹³Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland,
 USA; ¹⁴Department of Pathology, University of Maryland School of Medicine, Baltimore,
 Maryland, USA; ¹⁵Department of Biomedical and Clinical Sciences "Luigi Sacco," University
 of Milan Medical School, Milan, Italy; ¹⁶Department of Laboratory Medicine, University
 Hospital Padova, Italy; ¹⁷Cliniques Universitaires St-Luc and Universite Catholique de
 Louvain, Brussels, Belgium; ¹⁸Liverpool Hospital and University of New South Wales,
 Sydney, Australia; ¹⁹Roche Diagnostics Germany, Penzberg, Germany; ²⁰Emergency
 Department, University Hospital Zürich, Switzerland; ²¹Emergency Department,
 Kantonsspital Liestal, Switzerland..

ACKNOWLEDGEMENTS

We thank the patients who participated in the study, the staff of the EDs, the research coordinators, and the laboratory technicians (particularly Esther Garrido, Irina Klimmeck, Christine Kruse, Sabrina Laule, and Fausta Chiaverio) for their most valuable efforts.

Disclosures

Dr. Mueller has received research grants from the Swiss National Science Foundation and the Swiss Heart Foundation, the European Union, the Cardiovascular Research Foundation Basel, 8sense, Abbott, ALERE, Astra Zeneca, Beckman Coulter, Biomerieux, BRAHMS, Critical Diagnostics, Nanosphere, Roche, Siemens, Singulex, and the University Hospital Basel, as well as speaker or consulting honoraria from Abbott, ALERE, Astra Zeneca, BG Medicine, Biomerieux, BMS, Boehringer Ingelheim, BRAHMS, Cardiorientis, Daiichi Sankyo, Novartis, Roche, Sanofi, Singulex, and Siemens. Dr. Cullen reports grants from Roche and from Abbott, during the conduct of the study. Grants from Roche, grants and personal fees from Abbott Diagnostics, grants from Siemens, grants from Radiometer, personal fees from AstraZeneca, grants from Alere, outside the submitted work. Dr. Lindahl has served as a consultant for Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare Diagnostics, Radiometer Medical, bioMérieux Clinical Diagnostics, Philips Healthcare, and Fiomidiagnostics AB. Dr. Reichlin has received research grants from the Swiss National Science Foundation (PASMP3-136995), the Swiss Heart Foundation, the University of Basel, the Professor Max Cloetta Foundation and the Department of Internal Medicine, University Hospital Basel as well as speaker's honoraria from Brahms and Roche. Dr. Giannitsis has received honoraria for lectures from Roche Diagnostics, BRAHMS, ThermoFisher and Mitsubishi Chemical Europe. Dr. Christ has received research support and speaking honoraria from Roche, ThermoFisher, and Novartis. Dr. Twerenbold reports speaker honoraria from Brahms and Roche. Dr. Parsonage reports grants from Roche and from Abbott, during the

conduct of the study and grants from Roche, grants and personal fees from Abbott
Diagnostics, grants from Siemens, grants from Radiometer, personal fees from AstraZeneca,
non-financial support from Bayer, personal fees from Hospira, grants from Alere, outside the
submitted work. Dr. Rubini Gimenez has received speaking honoraria from Abbott and a
research grant from the Swiss Heart Foundation. Dr. Boeddinghaus has received speaking
Honoraria from Siemens. Dr. Bendig is an employee of Roche Diagnostics. Dr. Pickering is
supported by a Senior Research Fellowship from the Canterbury Medical Research
Foundation, Emergency Care Foundation and Canterbury District Health.

All other authors declare that they have no conflict of interest with this study.

Thomas Nestelberger, Jasper Boeddinghaus, Raphael Twerenbold, (cohort #1 and #3), Jaimi
Greenslade (cohort #2), and Christian Müller had full access to all of the data in the study and
take responsibility for the integrity of the data and the accuracy of the data analysis.

The Corresponding Author has the right to grant on behalf of all authors and does grant on
behalf of all authors, an exclusive licence (or nonexclusive for government employees) on a
worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if
accepted) to be published in HEART editions and any other BMJ PGL products to exploit all
subsidiary rights"

Sources of Funding

Cohort #1 (APACE) was supported by research grants from the Swiss National Science
Foundation, the Swiss Heart Foundation, the European Union, the Cardiovascular Research
Foundation Basel, the University Hospital Basel, Abbott, Beckman Coulter, Biomerieux,
BRAHMS, Roche, Nanosphere, Siemens, Singulex, and 8sense. Cohort #2 (ADAPT) was
supported by Queensland Emergency Medicine Research Foundation, Christchurch Heart

428 Institute and Health Research Council and Heart Foundation of New Zealand, Christchurch

429 Emergency Care Foundation. Cohort #3 (TRAPID-AMI) was sponsored by Roche.

430

REFERENCES

1. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* [Internet]. 2013 Jan 29 [cited 2014 Jul 10];61(4):e78-140. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23256914>
2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Socie. *Eur Heart J* [Internet]. 2017 Aug 26; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28886621>
3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* [Internet]. 2018 Aug 25; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30165617>
4. Cai Q, Mehta N, Sgarbossa EB, Pinski SL, Wagner GS, Califf RM, et al. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? *Am Heart J* [Internet]. Mosby, Inc.; 2013 Sep [cited 2013 Nov 10];166(3):409–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24016487>
5. Rokos IC, French WJ, Mattu A, Nichol G, Farkouh ME, Reiffel J, et al. Appropriate Cardiac Cath Lab activation: Optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. *Am Heart J* [Internet]. Mosby, Inc.; 2010;160(6):995–1003.e8. Available from: <http://dx.doi.org/10.1016/j.ahj.2010.08.011>
6. Larson DM, Menssen KM, Sharkey SW, Duval S, Schwartz RS, Harris J, et al. “False-positive” cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. *JAMA*. 2007;298(23):2754–60.
7. Erne P, Iglesias JF, Urban P, Eberli FR, Rickli H, Simon R, et al. Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice. *Am Heart J* [Internet]. 2017 Feb;184:106–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28224924>
8. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. [Internet]. *The New England journal of medicine*. 2009. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19710484>
9. Neumann JT, Sörensen NA, Rübsamen N, Ojeda F, Schäfer S, Keller T, et al. Right bundle branch block in patients with suspected myocardial infarction. *Eur Hear journal Acute Cardiovasc care* [Internet]. 2018 Oct 26;2048872618809700. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30362813>
10. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, et al. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial

476 Infarction. *J Am Coll Cardiol* [Internet]. 2017 Sep 26;70(13):1558–68. Available from:
477 <http://www.ncbi.nlm.nih.gov/pubmed/28935032>

478 11. Twerenbold R, Boeddinghaus J, Nestelberger T, Wildi K, Rubini Gimenez M,
479 Badertscher P, et al. Clinical Use of High-Sensitivity Cardiac Troponin in Patients
480 With Suspected Myocardial Infarction. *J Am Coll Cardiol*. 2017;70(8).

481 12. Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E,
482 et al. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis
483 of myocardial infarction. *Eur Heart J* [Internet]. 2018 Aug 29; Available from:
484 <http://www.ncbi.nlm.nih.gov/pubmed/30169752>

485 13. Cullen L, Mueller C, Parsonage W a., Wildi K, Greenslade JH, Twerenbold R, et al.
486 Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-
487 day outcomes in emergency department patients with possible acute coronary
488 syndrome. *J Am Coll Cardiol* [Internet]. 2013 Oct 1;62(14):1242–9. Available from:
489 <http://linkinghub.elsevier.com/retrieve/pii/S0735109713014101>

490 14. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, DeFilippi C, McCord J, et al.
491 Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial
492 Infarction With High-Sensitivity Cardiac Troponin T. *Ann Emerg Med* [Internet]. 2016
493 Jul 8;68(1):76–87.e4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26794254>

494 15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD
495 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*
496 [Internet]. 2015;351:h5527. Available from:
497 <http://www.ncbi.nlm.nih.gov/pubmed/26511519>

498 16. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, et al.
499 Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence
500 of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue
501 Plasminogen Activator for Occluded Coronary Arteries) Investigators. *N Engl J Med*
502 [Internet]. 1996 Feb 22;334(8):481–7. Available from:
503 <http://www.ncbi.nlm.nih.gov/pubmed/8559200>

504 17. Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-elevation
505 myocardial infarction in the presence of left bundle branch block with the ST-elevation
506 to S-wave ratio in a modified Sgarbossa rule. *Ann Emerg Med* [Internet]. Elsevier Inc.;
507 2012 Dec [cited 2014 Jan 14];60(6):766–76. Available from:
508 <http://www.ncbi.nlm.nih.gov/pubmed/22939607>

509 18. Meyers HP, Limkakeng AT, Jaffa EJ, Patel A, Theiling BJ, Rezaie SR, et al.
510 Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting
511 of left bundle branch block: A retrospective case-control study. *Am Heart J* [Internet].
512 2015 Dec;170(6):1255–64. Available from:
513 <http://www.ncbi.nlm.nih.gov/pubmed/26678648>

514 19. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC
515 Guidelines for the management of acute coronary syndromes in patients presenting
516 without persistent ST-segment elevation. *Eur Heart J*. 2016 Jan;37(3):267–315.

517 20. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. One-
518 hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac
519 troponin T. *Arch Intern Med* [Internet]. 2012 Sep;172(16):1211–8. Available from:
520 <http://archinte.jamanetwork.com/article.aspx?articleid=1309579>

21. Al-Faleh H, Fu Y, Wagner G, Goodman S, Sgarbossa E, Granger C, et al. Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. *Am Heart J* [Internet]. 2006 Jan;151(1):10–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16368285>
22. Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, et al. Diagnosing acute myocardial infarction in patients with left bundle branch block. *Am J Cardiol* [Internet]. Elsevier Inc.; 2011 Sep 15 [cited 2013 Dec 6];108(6):782–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21726838>
23. Kontos MC, Aziz HA, Chau VQ, Roberts CS, Ornato JP, Vetrovec GW. Outcomes in patients with chronicity of left bundle-branch block with possible acute myocardial infarction. *Am Heart J* [Internet]. Mosby, Inc.; 2011 Apr [cited 2014 Jan 14];161(4):698–704. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21473968>
24. Chang AM, Shofer FS, Tabas JA, Magid DJ, McCusker CM, Hollander JE. Lack of association between left bundle-branch block and acute myocardial infarction in symptomatic ED patients. *Am J Emerg Med* [Internet]. Elsevier Inc.; 2009 Oct [cited 2014 Jan 12];27(8):916–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19857407>
25. Pera VK, Larson DM, Sharkey SW, Garberich RF, Solie CJ, Wang YL, et al. New or presumed new left bundle branch block in patients with suspected ST-elevation myocardial infarction. *Eur Hear journal Acute Cardiovasc care* [Internet]. 2018 Apr;7(3):208–17. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29064258>
26. Dodd KW, Elm KD, Smith SW. Comparison of the QRS Complex, ST-Segment, and T-Wave Among Patients with Left Bundle Branch Block with and without Acute Myocardial Infarction. *J Emerg Med* [Internet]. 2016 Jul 31;51(1):1–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27041492>
27. Neeland IJ, Kontos MC, de Lemos JA. Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. *J Am Coll Cardiol* [Internet]. 2012;60:96–105. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22766335>
28. Li SF, Walden PL, Marcilla O, Gallagher EJ. Electrocardiographic diagnosis of myocardial infarction in patients with left bundle branch block. *Ann Emerg Med* [Internet]. 2000 Dec;36(6):561–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11097695>
29. Jain S, Ting HT, Bell M, Bjerke CM, Lennon RJ, Gersh BJ, et al. Utility of left bundle branch block as a diagnostic criterion for acute myocardial infarction. *Am J Cardiol* [Internet]. Elsevier Inc.; 2011 Apr 15;107(8):1111–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21296327>
30. Mehta N, Huang HD, Bandali S, Wilson JM, Birnbaum Y. Prevalence of acute myocardial infarction in patients with presumably new left bundle-branch block. *J Electrocardiol* [Internet]. Elsevier Inc.; 2012 [cited 2013 Dec 6];45(4):361–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22575807>
31. Shlipak MG, Go AS, Frederick PD, Malmgren J, Barron H V, Canto JG. Treatment and outcomes of left bundle-branch block patients with myocardial infarction who present without chest pain. National Registry of Myocardial Infarction 2 Investigators. *J Am Coll Cardiol* [Internet]. 2000 Sep;36(3):706–12. Available from:

567 <http://www.ncbi.nlm.nih.gov/pubmed/10987588>

568

Figure Legends

Figure 1 Integrated diagnostic work-up in cohort #1

Flowchart representing the integrated diagnostic work-up for patients presenting with left bundle branch block and suspected acute myocardial infarction in cohort #1 using hs-cTnT.

AMI: acute myocardial infarction; LBBB: left bundle branch block; (h)s-cTn: (high) sensitivity-cardiac troponin; pts: patients

Figure 2 Integrated diagnostic work-up in cohort #2

Flowchart representing the integrated diagnostic work-up for patients presenting with left bundle branch block and suspected acute myocardial infarction in cohort #2 using hs-cTnI. 1

Table 1 Baseline characteristics in Cohort #1

	all LBBB (n= 140, 100%)		LBBB no AMI (n=95, 68%)		LBBB and AMI (n=45, 32%)		p-value no AMI/AMI
Age, years, median (IQR)	78	(67 - 84)	74	(63 - 81)	82	(76 - 86)	<0.001
Male, sex, n %	93	66%	67	71%	26	58%	0.136
BMI, median (IQR)	27	(24 - 31)	27	(24 - 31)	25	(22 - 30)	0.60
Risk factors, n %							
Hypertension	122	87%	80	84%	42	93%	0.132
Hypercholesterolemia	92	66%	58	61%	34	76%	0.091
Diabetes	25	18%	14	15%	11	25%	0.143
Current smoking	16	11%	10	11%	6	13%	0.63
History of smoking	67	48%	42	44%	25	56%	0.209
History, n %							
Coronary artery disease	76	54%	41	43%	35	78%	<0.001
Previous myocardial infarction	54	39%	26	27%	28	62%	<0.001
Previous revascularization	54	39%	33	35%	21	47%	0.176
Peripheral artery disease	12	8.6%	4	4.2%	8	18%	0.007
Previous stroke	16	11%	7	7.4%	9	20%	0.028
Positive family history	21	17%	17	20%	4	11%	0.27
Medication at entry, n %							
Aspirin/Thienopyridin	77	55%	49	52%	28	62%	0.24
Betablockers	74	53%	47	50%	27	60%	0.24
ACE/AT2- Inhibitors	92	66%	57	60%	35	78%	0.038
Ca- Antagonists	31	22%	16	17%	15	33%	0.028
Marcoumar/Warfarin	27	19%	17	18%	10	22%	0.54
Nitrates	37	26%	21	22%	16	36%	0.092
Measurements/Findings							
Systolic BP, median (IQR)	136	(118 - 161)	138	(121 - 163)	134	(115 - 152)	0.110
Pulse, median (IQR)	82	(67 - 96)	78	(64 - 90)	88	(75 - 99)	0.011
eGFR, mL/min/m2, median	69	(48 - 86)	77	(60 - 91)	47	(35 - 69)	<0.001

(IQR)							
BNP pg/ml, median (IQR)	672	(199 - 1272)	421	(168 - 1121)	919	(327 - 1643)	0.105
Coronary Angiography n (%)	49	35%	24	25%	25	56%	<0.001
One vessel disease	4	2.9%	3	3.2%	1	2.2%	1.000
Two vessel disease	12	8.6%	2	2.1%	10	22%	<0.001
Three vessel disease	21	15%	7	7.4%	14	31%	0.001
Coronary Intervention n (%)	20	14%	4	4.2%	16	36%	<0.001
Left main vessel	0	0.0%	0	0.0%	0	0.0%	n.a.
RIVA	7	5.0%	0	0.0%	7	16%	<0.001
RCX	8	5.7%	2	2.1%	6	13%	0.014
ACD	3	2.1%	1	1.1%	2	4.4%	0.24
Bypass Intervention	6	4.3%	2	2.1%	4	8.9%	0.084
More than one intervention	3	1.1%	1	1.1%	2	4.4%	0.24
CABG	3	2.1%	0	0.0%	3	6.7%	0.032

Table Legends: LBBB: left bundle branch block; IQR: interquartile range; ACE: angiotensin converting enzyme; AT1: angiotension 1; Ca: Calcium; ACS: acute coronary syndrome; BP: blood pressure; eGFR: estimated glomerular filtration rate; RIVA: Ramus interventricularis anterior;

RCX: Ramus circumflexus; ACD: Arteria coronaria dextra; CABG: coronary artery bypass graft

594

595

596

597

598

599

600

601

Table 2 Diagnostic performance of ECG criteria in all cohorts

	true- positive test result	false- negative test result	true- negative test result	false- positive test result	Accuracy % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	NPV % (95% CI)	PPV % (95% CI)
all cohorts									
ECG criteria 1 (5 points)	1	74	172	0	70% (64 - 76%)	1% (0 - 7%)	100% (98 - 100%)	70% (64 - 75%)	100% (21 - 100%)
ECG criteria 2 (3 points)	2	73	171	1	70% (64 - 76%)	3% (1 - 9%)	99% (97 - 100%)	70% (64 - 76%)	67% (21 - 94%)
ECG criteria 3 (2 points)	5	70	164	8	68% (62 - 74%)	7% (2 - 15%)	95% (91 - 98%)	70% (64 - 76%)	39% (18 - 65%)
ECG Score $\geq$ 3 points	2	73	171	1	70% (64 - 76%)	3% (0 - 9%)	99% (97 - 100%)	70% (69 - 71%)	67% (16 - 96%)
Alternative ECG criteria 1 (2 points)	8	67	169	3	72% (66 - 77%)	11% (5 - 20%)	98% (95 - 100%)	72% (66 - 77%)	72% (42 - 91%)
Alternative ECG Score $\geq$ 3 points	9	66	166	6	71% (65 - 76%)	12% (6 - 22%)	97% (93 - 99%)	72% (70 - 73%)	60% (36 - 80%)

Table legends: AUC: area under the curve; CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value, n.a.: not applicable

602

Table 3 Diagnostic performance hs-cTn (T and I) and s-cTnI in LBBB patients in all 3 cohorts

cohort #1	AUC	(95% CI)	Cutoff values for PPV 80%	patients, n	true- positive test result, n	false- negative test result, n	true- negative test result, n	false- positive test result, n	Sensitivity % (95% CI)	Specificity % (95% CI)	NPV % (95% CI)	PPV % (95% CI)
hs-cTnT 0h	0.91	(0.85 - 0.96)	≥42ng/L	140	36	9	86	9	80% (66 - 89%)	91% (83 - 95%)	91% (83 - 95%)	80% (66 - 89%)
hs-cTnT Abs Change 0h/1h	0.91	(0.84 - 0.98)	≥3ng/L	120	32	6	75	7	84% (70 - 93%)	92% (83 - 96%)	93% (85 - 97%)	82% (67 - 91%)
hs-cTnI 0h	0.89	(0.83 - 0.95)	≥45ng/L	132	29	13	83	7	69% (54 - 81%)	92% (85 - 96%)	87% (78 - 92%)	81% (65 - 90%)
hs-cTnI Abs Change 0h/1h	0.96	(0.91 - 1.00)	≥4ng/L	111	30	3	71	7	91% (76 - 97%)	91% (83 - 96%)	96% (89 - 99%)	81% (66 - 91%)
s-cTnI 0h	0.97	(0.94 - 1.00)	≥53ng/L	87	28	4	49	6	87% (72 - 95%)	89% (78 - 95%)	93% (82 - 97%)	82% (66 - 92%)
s-cTnI Abs Change 0h/1h	0.93	(0.85- 1.00)	≥10ng/L	75	21	4	45	5	84% (65 - 94%)	90% (79 - 96%)	92% (81 - 97%)	81% (62 - 92%)
cohort #2												
hs-cTnT 0h	0.96	(0.85-0.99)	≥42ng/L	45	9	3	31	2	75% (43-95%)	94% (80-99%)	91% (76-98%)	82% (48-98%)
hs-cTnT Abs Change 0h/2h	0.89	(0.74-0.96)	≥3ng/L	42	9	3	24	6	75% (43-95%)	80% (61-92%)	89% (71-98%)	60% (32-84%)
hs-cTnI 0h	0.93	(0.83-0.98)	≥45ng/L	56	13	3	36	4	81% (56-94%)	90% (80-93%)	92% (79-98%)	78% (54-89%)
hs-cTnI Abs Change 0h/2h	0.95	(0.85-0.99)	≥4ng/L	56	15	1	33	7	94% (70-100%)	83% (67-93%)	97% (85-100%)	68% (45-86%)
cohort #3												
hs-cTnT 0h	0.81	(0.67 - 0.95)	≥42ng/L	37	6	7	23	1	46% (23 - 71%)	96% (80 - 99%)	77% (59 - 88%)	86% (49 - 97%)
hs-cTnT Abs Change 0h/1h	0.88	(0.77 - 0.99)	≥3ng/L	37	10	3	17	7	77% (50 - 92%)	71% (51 - 85%)	85% (64 - 95%)	59% (36 - 78%)

hs-cTnI 0h	0.96	(0.91 - 1.00)	≥53ng/L	36	1	11	24	0	8% (1 - 35%)	100% (86 - 100%)	69% (52 - 81%)	100% (21 - 100%)
hs-cTnI Abs Change 0h/1h	0.92	(0.81 - 1.00)	≥11ng/L	36	9	3	23	1	75% (47 - 91%)	96% (80 - 99%)	88% (71 - 96%)	90% (60 - 98%)

Table legends: LBBB: left bundle branch block; hs-cTn: high sensitivity cardiac troponin; AUC: area under the curve; CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value

n: number of patients

604